Dr. Jie D’Elia is the Chief Executive Officer of SystImmune, Inc., a pioneering clinical-stage biopharmaceutical company focused on developing novel therapeutic multi-specific antibodiesand antibody-drug conjugates (ADCs).
Before joining SystImmune in April 2024, Dr. D’Elia was the Senior Vice President of Business Development, Oncology, Hematology, and Cell Therapy at Bristol Myers Squibb (“BMS”). During her eleven years at BMS, she made significant impact to BMS’s pipeline evolution through multiple strategic partnerships and acquisitions in therapeutic areas ranging from oncology, hematology, cardiovascular, virology, fibrosis, and cell therapy. Prior to BMS, Dr. D’Elia served as the Vice President and Global Head of Business Development at Simcere Pharmaceutical. She previously worked at AstraZeneca, Boston Consulting Group and Baxter Healthcare. Throughout her career in the biopharmaceutical industry, Dr. D’Elia has orchestrated over $40 billion in strategic partnerships and mergers and acquisitions, leveraging her strong business expertise and deep industry knowledge.
Dr. D’Elia received her Ph.D. from the College of Pharmacy at the University of Texas at Austin and her MBA from Columbia Business School.